Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Raises Price Target to $15
Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Raises Price Target to $15
摩根士丹利維持對Amicus Therapeutics的同等權重,將目標股價提高至15美元
Morgan Stanley analyst Andrew Galler maintains Amicus Therapeutics (NASDAQ:FOLD) with a Equal-Weight and raises the price target from $14 to $15.
摩根士丹利分析師安德魯·蓋勒維持Amicus Therapeutics(納斯達克股票代碼:FOLD)的權重持平,並將目標股價從14美元上調至15美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。